Teva to Report First Quarter 2017 Financial Results on May 11, 2017

JERUSALEM–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it
will release its first quarter 2017 financial results on Thursday, May
11, 2017 at 7:00 a.m. ET.

Teva will host a conference call and live webcast on the same day, at
8:00 a.m. ET to discuss its first quarter 2017 results and overall
business environment. A Question & Answer session will follow this
discussion.

In order to participate, please dial the following numbers (at least 10
minutes before the scheduled start time): United States 1-866-869-2321;
Canada 1-866-766-8269 or International +44(0) 203 0095710; passcode:
97789997. For a list of other international toll-free numbers, click here.

A live webcast of the call will also be available on Teva’s website at: www.ir.tevapharm.com.
Please log in at least 10 minutes prior to the conference call in order
to download the applicable audio software.

Following the conclusion of the call, a replay of the webcast will be
available within 24 hours on the Company’s website. The replay can also
be accessed until June 11, 2017, 9:00 a.m. ET by calling United States
1-866-247-4222; Canada 1-866-878-9237 or International +44(0)
1452550000; passcode: 97789997.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by approximately 200 million
patients in 100 markets every day. Headquartered in Israel, Teva is the
world’s largest generic medicines producer, leveraging its portfolio of
more than 1,800 molecules to produce a wide range of generic products in
nearly every therapeutic area. In specialty medicines, Teva has the
world-leading innovative treatment for multiple sclerosis as well as
late-stage development programs for other disorders of the central
nervous system, including movement disorders, migraine, pain and
neurodegenerative conditions, as well as a broad portfolio of
respiratory products. Teva is leveraging its generics and specialty
capabilities in order to seek new ways of addressing unmet patient needs
by combining drug development with devices, services and technologies.
Teva’s net revenues in 2016 were $21.9 billion. For more information,
visit www.tevapharm.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170406005071/en/